论文部分内容阅读
目的:观察阿德福韦酯联合双虎清肝颗粒抗肝纤维化的临床疗效。方法:将60例慢性乙型肝炎患者随机分为治疗组与对照组各30例。治疗组予阿德福韦酯片联合双虎清肝颗粒治疗,对照组单予阿德福韦酯片治疗,疗程均为18个月。观察两组治疗前后症状与体征改善情况以及肝功能、肝纤维化4项等指标的变化情况。结果:总有效率治疗组为86.67%,对照组为53.33%,两组比较,差异有统计学意义(P<0.01);症状消失率治疗组为83.33%,对照组为63.33%、体征改善率治疗组为74.07%(20/27),对照组为46.15%(12/26),两组比较,差异均有统计学意义(P<0.05);治疗组肝功能和肝纤维化4项水平治疗前后组内比较,差异均有统计学意义(P<0.01),治疗组肝纤维化4项水平改善优于对照组,差异均有统计学意义(P<0.05);两组HBV-DNA水平均显著下降,治疗组下降幅度为(3.75±1.67)log10Copies/m L,对照组下降幅度为(3.23±1.89)log10Copies/m L,两组比较,差异无统计学意义(P>0.05);e抗原血清学转换率治疗组为36.67%,对照组为13.33%,两组比较,差异有统计学意义(P<0.01);两组肝脏炎症和纤维化程度较治疗前均有明显改善(P<0.01)。结论:阿德福韦酯联合双虎清肝颗粒能改善慢性乙型肝炎患者肝纤维化,值得临床推广。
Objective: To observe the clinical effect of adefovir dipivoxil combined with double tiger qinggan granule on liver fibrosis. Methods: Sixty patients with chronic hepatitis B were randomly divided into treatment group and control group, 30 cases each. Treatment group to adefovir dipivoxil tablets combined with double tiger liver particles, the control group was treated with adefovir dipivoxil tablets, the treatment was 18 months. The symptoms and signs of the two groups were observed before and after treatment as well as changes of liver function, liver fibrosis and other indicators. Results: The total effective rate was 86.67% in the treatment group and 53.33% in the control group. There was significant difference between the two groups (P <0.01). The symptom disappearance rate was 83.33% in the treatment group and 63.33% in the control group The treatment group was 74.07% (20/27), while the control group was 46.15% (12/26). There were significant differences between the two groups (P <0.05). The treatment group had 4 levels of liver function and liver fibrosis (P <0.01). The improvement of 4 levels of liver fibrosis in the treatment group was better than that in the control group (P <0.05). The levels of HBV-DNA in both groups were significantly lower than those in the control group (3.75 ± 1.67) log10 Copies / m L in the treatment group and (3.23 ± 1.89) log10 Copies / m L in the control group, the difference was not statistically significant (P> 0.05); e antigen The seroconversion rate was 36.67% in the treatment group and 13.33% in the control group, with significant difference between the two groups (P <0.01). The degree of liver inflammation and fibrosis in both groups were significantly improved (P <0.01) ). Conclusion: Adefovir dipivoxil combined with Shuang Hu Qing Gan Granules can improve liver fibrosis in patients with chronic hepatitis B, which is worthy of clinical promotion.